A SAGE Publishing Gold #openaccess journal | Publishing innovative clinically focused articles on the medical treatment of cancer| PubMed Indexed | IF: 4.2
Therapeutic Advances in Medical Oncology
Loading...
How do physicians approach treatment decisions for young patients with HR+, HER2‑ early #breastcancer? This Latin American survey provides insights into real‑world clinical practice.
🔗 buff.ly/isnY3xJ
#BreastCancer #YoungPatients #ClinicalPractice #Oncology
🆕 A multicenter phase II randomized trial evaluates Endostar + concurrent chemoradiotherapy in locally advanced cervical cancer.
🔗 Read the full article: buff.ly/mQhOTsg
#CervicalCancer #OncologyResearch #ClinicalTrials #Radiotherapy
📣 Call for Papers
A Collection in Ther Adv Med Oncol focuses on #ADCs in gynecologic cancers, including ovarian, endometrial, and cervical malignancies. We welcome clinically relevant research and reviews.
🗓️ Deadline: 26 Feb 2027
buff.ly/30K8r13
#GynecologicOncology #CancerResearch #OpenCall
🚨 Call for Papers
The KRAS era is here - now we need strategies to anticipate & overcome resistance in pancreatic cancer.
Submit by Mar 1, 2027: KRAS pathways, combos, resistance mechanisms, new targets & models.
🔗 buff.ly/eMwzb2N
#PDAC #KRAS #TargetedTherapy #CancerResearch
A large French multicenter cohort study examines how age influences clinical characteristics, treatment patterns, and outcomes in #BiliaryTractCancer, highlighting differences in unresectable disease and comparable survival after resection.
buff.ly/6PIVm3G
#Cholangiocarcinoma #GeriatricOncology
🆕 This study explores afatinib dose optimization to improve outcomes while reducing toxicities in advanced EGFR‑mutated NSCLC patients in Vietnam.
🔗 buff.ly/XucLdR2
#LungCancer #NSCLC #EGFR #TargetedTherapy #Oncology
📢 This phase Ib/II study investigates the addition of neoadjuvant neratinib to standard therapy in patients with inflammatory #breastcancer, including those with HER2+ and HR+/HER2‑ disease across stage III and IV settings.
👉 Read the full article:
buff.ly/bFwUuVM
#InflammatoryBreastCancer #HER2 #
A narrative review summarises recent advances and key trials of radionuclide therapies, including ²²³Ra, ¹⁷⁷Lu‑labelled agents, and emerging α‑emitters, in metastatic castration‑resistant #ProstateCancer.
Ther Adv Med Oncol
buff.ly/XQWUg2J
#RadionuclideTherapy
🆕 Nationwide real‑world data reveal how treatment gaps are linked to survival outcomes in #HepatocellularCarcinoma, highlighting unmet needs in routine care.
🔗 buff.ly/BF3QeGz
#HCC #LiverCancer #CancerOutcomes #RealWorldEvidence
We invites submissions to the Collection “Advances in Acute Myeloid Leukemia (AML) Therapy in the Precision Medicine Era.”
Submission deadline: 19 Feb 2027
buff.ly/xsqkygl
#AML #PrecisionOncology #HematologicMalignancies #MRD
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Subscription and open access journals from Sage, the world's leading independent academic publisher.
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a huge challenge. Newer radionuclides, such as 223Ra, 177Lu, 225Ac, etc., have ...
